Stopping Trials Early for Commercial Reasons: The Risk-Benefit Relationship as a Moral Compass
Journal of Medical Ethics 2005 July; 31(7): 410-414
Decisions by industry sponsors to end clinical trials early for commercial reasons have been the subject of controversy. I argue that the principal consideration in assessing these decisions ought to be the way in which the termination would affect the trial's risk-benefit relationship. If there is not yet sufficient benefit to be gained from the study to offset the risks to which participants were exposed and it is expected that important scientific information would be obtained if the trial were continued, early termination constitutes an unethical alteration of the risk-benefit relationship. This violates the grounds on which permission is given to conduct human research, patients consent to participate, and investigators agree to conduct studies. These knowable and avoidable changes in risk-benefit relationship should generally be seen as impermissible.
Showing items related by title, author, creator and subject.
The Placebo Phenomenon and Medical Ethics: Rethinking the Relationship Between Informed Consent and Risk-Benefit Assessment Miller, Franklin G; Colloca, Luana (2011-08)It has been presumed within bioethics that the benefits and risks of treatments can be assessed independently of information disclosure to patients as part of the informed consent process. Research on placebo and nocebo ...
Calculating risk/benefit in X-linked severe combined immune defieciency disorder (X-SCID) gene therapy trials: the task of ethical evaluation Swazo, Norman K. (2006-10)In response to adverse events in retroviral gene therapy clinical trials conducted in France to correct for X-linked severe combined immune deficiency disorder (X-SCID), an advisory committee of the Food and Drug Administration ...